Stock Market News

Torrent Power said open capacity risk is minimal and curtailment has not impacted its renewable projects 🔋, while it targets commissioning 1.2–1.4 GW of new renewable capacity in FY27 under secured PPAs.

Torrent Power plans a strategic pivot toward renewables and pumped storage hydro to drive large-scale green energy growth, management said in a concall update 🔋

Torrent Power plans a big rise in FY27 capital expenditure over FY26’s ₹8,720 crore, focusing on renewables and energy storage growth 🔋 while prioritising financing costs and leverage, concall update

Torrent Power said it expects uninterrupted LNG supply despite global tensions 🔋, focusing on fuel access and fixed cost recovery to protect thermal margins amid high spot gas prices.

Schaeffler India opened a high-performance research center at IISc Bengaluru to boost research capabilities 📩 and signed a major research deal with IISc for industry collaboration

₹23.90 crore worth shares (~5.09 lakh) of IIFL Finance exchanged on NSE at ₹470 📊

Dixon said in an interview that news on the Vivo–Dixon joint venture will be coming soon 📩

₹28.46 crore worth shares (~22.43 lakh) of Indian Energy Exchange exchanged on NSE at ₹126.88 💰

₹18.06 crore worth shares (~1.03 lakh) of Bharti Airtel exchanged on NSE at ₹1,757 💰

KEI Industries said income tax search operations are over and it is working alongside authorities 🧾

Sakar Healthcare anticipates FY27 to be a significant year, with boosted exports and rising oncology volumes 📈 supporting further growth

Dr Reddy’s expects semaglutide pricing around $30+ per unit (minimum $25) 💰, sees annual biosimilar sales at $500Mn–$700Mn by FY29 and plans capex of about ₹2,000 crore in FY27

Dr Reddy’s plans to keep EBITDA margin near 20% without semaglutide and targets ~25% with semaglutide sales 📊; it sees 60–70 lakh units by end-2026 and 100–110 lakh pens per quarter in FY2027.

Dr Reddy’s expects SG&A to stay around FY26 levels 📊, with R&D at 7%–8% of adjusted revenue and FY27 effective tax rate seen at 24%–25%; North America targets double-digit growth ex-lenalidomide.

Dr Reddy’s Labs expects core business to sustain double-digit growth next year 📈, and projects FY27 gross margins above 50% on cost savings, efficiency gains and new products like semaglutide

GRSE expects NGC project revenue to start in FY28 second half 📊, with most revenue recognised from FY29; management also expects healthy FY27 revenue and aims to keep EBITDA margins consistent through FY29

GRSE expects shipbuilding capacity to increase to 32 from 28 by year-end due to ongoing upgrades 📈 and says it is focusing on higher-margin projects for future orders

European ship owners are turning to India for vessels amid congestion in China and Korea, with GRSE planning new technology such as autonomous platforms to build momentum over 3–5 years 📩